Figure 1.
Diagram of the clinical study.
“unable”: patients who were reached but unable to answer to the questionnaire, “lost”: patient lost of follow up until the end of the study, “temporally lost”: not reached at a specific timepoint, “death”: dead patients.
Figure 2.
Evolution and characterization of arthralgia in CHIKV patients.
(A) Percentage of patients with arthralgia among participating patients, (B) localization of arthralgia among patients with arthralgia, (C) number of arthralgia sites among the 76 patients answering at every time point and having arthralgia, (D) complete model presenting the probability for one joint to be painful depending on its previous state.
Table 1.
Clinical signs and treatment in arthralgic and non-arthralgic patients 36 months after the acute phase.
Table 2.
Impact of arthralgia on daily life for patients at M36.
Table 3.
Identification of risk factors for persistence of arthralgia 14 months after CHIKV acute disease (univariate analysis).
Figure 3.
Distinctive markers in serum of patients with arthralgia (ART+ in black) versus patients without arthralgia (ART−, in white) at M36.
SD: standard deviation, results of Mann Whitney test are shown. * p<0.05, q = 0.056.
Table 4.
Analytes titrated in arthralgic and non arthralgic patients 36 months after the acute phase.
Table 5.
Features of patients with chronic CHIKV-associated arthralgia.